EPRSQ: AI 评分 46/100 — AI 分析 (4月 2026)

EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing biosimilar therapeutics. The company filed for liquidation under Chapter 7 bankruptcy in 2016.

Key Facts: Price: $0.00 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing biosimilar therapeutics. The company filed for liquidation under Chapter 7 bankruptcy in 2016.

EPIRUS Biopharmaceuticals aimed to revolutionize treatment for inflammatory diseases and ultra-rare blood disorders through biosimilar development, offering potential cost-effective alternatives, before filing for Chapter 7 liquidation in 2016, ceasing operations and development.

EPRSQ是做什么的？

Founded in 2011 and headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company dedicated to developing, manufacturing, and commercializing biosimilar therapeutics on a global scale. The company's core strategy revolved around creating biosimilar versions of established biologic drugs, offering potentially more affordable treatment options for a range of diseases. Their lead product candidate was BOW015, a biosimilar version of Remicade (infliximab), targeting inflammatory diseases. The pipeline also included BOW050, a biosimilar of Humira (adalimumab); BOW070, a biosimilar of Actemra (tocilizumab); BOW080, a biosimilar of Soliris; and BOW100, a biosimilar of SIMPONI. These biosimilars were intended to treat a variety of conditions, including rheumatoid arthritis, inflammatory bowel disease, and ultra-rare blood disorders. EPIRUS established strategic collaborations and licensing agreements with companies like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A. to support its development and commercialization efforts. However, on July 25, 2016, EPIRUS Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court, effectively halting its operations and development programs.

EPRSQ的投资论点是什么？

Investing in EPRSQ is not advisable due to the company's Chapter 7 liquidation filing in 2016. The company's assets are being liquidated, and there is no ongoing business operation. The potential for return on investment is extremely low. The company's pipeline of biosimilar product candidates, including BOW015, BOW050, BOW070, BOW080, and BOW100, are no longer under development. The company's market capitalization is effectively zero, reflecting its defunct status. Investors should be aware of the high risk associated with investing in companies undergoing liquidation.

EPRSQ在哪个行业运营？

The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like ALNAQ, ARTH, GNRS, GWHP, and INTP operate in this space. The biosimilar market offers opportunities for companies to develop and commercialize cost-effective alternatives to existing biologic drugs. However, the industry also faces challenges such as patent disputes, regulatory hurdles, and pricing pressures. EPIRUS Biopharmaceuticals aimed to capitalize on the biosimilar market but ultimately failed due to financial constraints, leading to its liquidation.

Biotechnology

Healthcare

EPRSQ有哪些增长机遇？

Growth opportunity 1: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Growth opportunity 2: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Growth opportunity 3: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Growth opportunity 4: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Growth opportunity 5: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.

Lead product candidate BOW015 was a biosimilar version of Remicade (infliximab) targeting inflammatory diseases.
Pipeline included biosimilars for Humira (adalimumab), Actemra (tocilizumab), Soliris, and SIMPONI.
Collaborations with Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A.
Filed for Chapter 7 liquidation on July 25, 2016.
Market capitalization is $0.00B, reflecting its defunct status.

EPRSQ提供哪些产品和服务？

Developed biosimilar therapeutics.
Aimed to manufacture biosimilar versions of existing biologic drugs.
Focused on treatments for inflammatory diseases and ultra-rare blood disorders.
Sought to commercialize biosimilars globally.
Partnered with other pharmaceutical companies for development and distribution.
Filed for Chapter 7 liquidation in 2016.

EPRSQ如何赚钱？

Develop biosimilar versions of branded biologic drugs.
Out-license or co-develop biosimilars with partners.
Commercialize biosimilars directly or through partners.
Generate revenue through product sales and licensing fees.

Patients suffering from inflammatory diseases.
Healthcare providers prescribing biologic drugs.
Hospitals and clinics using biologic treatments.
Pharmaceutical companies partnering for distribution.

Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no competitive advantages associated with the company.

什么因素可能推动EPRSQ股价上涨？

Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

EPRSQ的主要风险是什么？

Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.
Ongoing: No ongoing business operations.
Ongoing: No potential for future revenue generation.

EPRSQ的核心优势是什么？

Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

EPRSQ的劣势是什么？

Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

EPRSQ有哪些机遇？

Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

EPRSQ面临哪些威胁？

Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

EPRSQ的竞争对手是谁？

Alnylam Pharmaceuticals, Inc. — Focuses on RNAi therapeutics. — (ALNAQ)
Arthritis Innovation Corp. — Focuses on treatments for arthritis. — (ARTH)
Genrus Biotech International, Inc. — Focuses on biotechnology. — (GNRS)
GWG Holdings, Inc. — Financial services company. — (GWHP)
Intercept Pharmaceuticals, Inc. — Focuses on treatments for liver diseases. — (INTP)

Key Metrics

Price: $0.00 (-99.00%)
Volume: 150
MoonshotScore: 46/100

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does EPIRUS Biopharmaceuticals, Inc. (EPRSQ) do?

EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company focused on developing, manufacturing, and commercializing biosimilar therapeutics. Its primary goal was to create more affordable versions of existing biologic drugs, targeting inflammatory diseases and ultra-rare blood disorders. However, the company filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs, and is no longer an active entity.

Is EPRSQ stock a good buy?

No, EPRSQ stock is not a good buy. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, indicating that the company is undergoing asset liquidation and has ceased its business operations. With a market capitalization of $0.00B and no ongoing business, there is virtually no potential for return on investment. Investing in EPRSQ carries an extremely high risk and is not recommended.

What are the risks of investing in EPRSQ?

The primary risk of investing in EPRSQ is the ongoing liquidation process due to the Chapter 7 bankruptcy filing. This means the company's assets are being sold off to pay creditors, and there are no ongoing business operations. There is a high probability of complete loss of investment, and investors should be aware of the significant financial risks involved with investing in a company undergoing liquidation.

What catalysts could move EPRSQ stock?

There are no catalysts that could move EPRSQ stock. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. With no ongoing business or active pipeline, there are no potential events or developments that could positively influence the stock price. The company's financial situation makes any positive movement highly improbable.

What is EPRSQ stock price target?

There is no EPRSQ stock price target available. Given that EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016 and has no ongoing business operations, analysts do not provide price targets for the stock. The company's financial status and liquidation process make it impossible to determine a meaningful price target.